Approaching clinical proteomics: current state and future fields of application in fluid proteomics

被引：91

作者：

Apweiler, Rolf ^{[2
]}

Aslanidis, Charalampos ^{[1
]}

Deufel, Thomas ^{[3
]}

Gerstner, Andreas ^{[4
]}

Hansen, Jens ^{[1
]}

Hochstrasser, Dennis ^{[5
]}

Kellner, Roland ^{[6
]}

Kubicek, Markus ^{[7
]}

Lottspeich, Friedrich ^{[8
]}

Maser, Edmund ^{[9
]}

Mewes, Hans-Werner ^{[10
]}

Meyer, Helmut E. ^{[11
]}

Muellner, Stefan ^{[12
]}

Mutter, Wolfgang ^{[13
]}

Neumaier, Michael ^{[14
]}

Nollau, Peter ^{[15
]}

Nothwang, Hans G. ^{[16
]}

Ponten, Fredrik ^{[17
]}

Radbruch, Andreas ^{[18
]}

Reinert, Knut ^{[19
]}

Rothe, Gregor ^{[20
]}

Stockinger, Hannes ^{[21
]}

Tarnok, Attila ^{[22
]}

Taussig, Mike J. ^{[23
]}

Thiel, Andreas ^{[18
]}

Thiery, Joachim ^{[24
]}

Ueffing, Marius ^{[25
]}

Valet, Guenther ^{[8
]}

Vandekerckhove, Joel ^{[26
]}

Verhuven, Wiltrud ^{[27
]}

Wagener, Christoph ^{[15
]}

Wagner, Oswald ^{[7
]}

Schmitz, Gerd ^{[1
]}

机构：

[1] Univ Regensburg, Inst Clin Chem & Lab Med, D-93042 Regensburg, Germany

[2] European Bioinformat Inst, Hinxton, England

[3] Univ Jena, Inst Clin Chem & Lab Diagnost, Jena, Germany

[4] Univ Bonn, Dept Otorhinolaryngol Surg, D-5300 Bonn, Germany

[5] Univ Geneva, Dept Pathol Clin Chem, Geneva, Switzerland

[6] E Merck AG, D-6100 Darmstadt, Germany

[7] Univ Vienna, Inst Med & Chem Lab Diagnost, Vienna, Austria

[8] Max Planck Inst Biochem, D-82152 Martinsried, Germany

[9] Univ Kiel, Inst Pharmacol & Toxicol, Kiel, Germany

[10] GSF, Inst Bioinformat, Neuherberg, Germany

[11] Ruhr Univ Bochum, Med Prote Ctr, Bochum, Germany

[12] Protagen, Dortmund, Germany

[13] PROFOS, Regensburg, Germany

[14] Univ Hosp Mannheim, Inst Clin Chem, Mannheim, Germany

[15] Univ Med Ctr Hamburg Eppendorf, Inst Clin Chem, Hamburg, Germany

[16] Tech Univ Kaiserslautern, Dept Anim Physiol, Kaiserslautern, Germany

[17] Uppsala Univ, Inst Genet & Pathol, Uppsala, Sweden

[18] German Rheumatism Res Ctr Berlin, Berlin, Germany

[19] Univ Berlin, Dept Math & Comp Sci, Berlin, Germany

[20] Lab Ctr Bremen, Bremen, Germany

[21] Univ Vienna, Dept Mol Immunol, Vienna, Austria

[22] Univ Leipzig, Dept Pediat Cardiol, Leipzig, Germany

[23] Babraham Inst Cambridge, Technol Res Grp, Cambridge, England

[24] Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany

[25] GSF Neuherberg, Inst Human Genet, Neuherberg, Germany

[26] Univ Ghent, Dept Med Prot Res, B-9000 Ghent, Belgium

[27] Waters, Eschborn, Germany

来源：

CLINICAL CHEMISTRY AND LABORATORY MEDICINE | 2009年 / 47卷 / 06期

关键词：

cerebrospinal fluid (CSF); clinical proteomics; fluid proteomics; mass spectrometry (MS); matrix assisted laser desorption/ionization (MALDI); preanalytical effects; standard operating procedures (SOP); surface-enhanced laser desorption/ionization (SELDI); FLIGHT-MASS-SPECTROMETRY; ENHANCED LASER-DESORPTION/IONIZATION; 2-DIMENSIONAL GEL-ELECTROPHORESIS; BRONCHOALVEOLAR LAVAGE FLUID; PROTEIN-PROTEIN INTERACTIONS; TRANSITIONAL-CELL CARCINOMA; DESORPTION-IONIZATION-TIME; INTRA-INDIVIDUAL VARIATION; MAGNETIC BEAD SEPARATION; FLOW-CYTOMETRIC ASSAYS;

D O I：

10.1515/CCLM.2009.167

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

The field of clinical proteomics offers opportunities to identify new disease biomarkers in body fluids, cells and tissues. These biomarkers can be used in clinical applications for diagnosis, stratification of patients for specific treatment, or therapy monitoring. New protein array formats and improved spectrometry technologies have brought these analyses to a level with potential for use in clinical diagnostics. The nature of the human body fluid proteome with its large dynamic range of protein concentrations presents problems with quantitation. The extreme complexity of the proteome in body fluids presents enormous challenges and requires the establishment of standard operating procedures for handling of specimens, increasing sensitivity for detection and bioinformatical tools for distribution of proteomic data into the public domain. From studies of in vitro diagnostics, especially in clinical chemistry, it is evident that most errors occur in the preanalytical phase and during implementation of the diagnostic strategy. This is also true for clinical proteomics, and especially for fluid proteomics because of the multiple pretreatment processes. These processes include depletion of high-abundance proteins from plasma or enrichment processes for urine where biological variation or differences in proteolytic activities in the sample along with preanalytical variables such as inter- and intra-assay variability will likely influence the results of proteomics studies. However, before proteomic analysis can be introduced at a broader level into the clinical setting, standardization of the preanalytical phase including patient preparation, sample collection, sample preparation, sample storage, measurement and data analysis needs to be improved. In this review, we discuss the recent technological advances and applications that fulfil the criteria for clinical proteomics, with the focus on fluid proteomics. These advances relate to preanalytical factors, analytical standardization and quality-control measures required for effective implementation into routine laboratory testing in order to generate clinically useful information. With new disease biomarker candidates, it will be crucial to design and perform clinical studies that can identify novel diagnostic strategies based on these techniques, and to validate their impact on clinical decision-making. Clin Chem Lab Med 2009;47:724-44.

引用

页码：724 / 744

页数：21

共 169 条

[1] The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins [J].